Bronchiectasis in Italy: data from the national registry IRIDE

Le résumé fourni par la source

There are limited reported data on bronchiectasis characteristics and management in Southern Europe, particularly in Italy. A secondary analysis of the Italian Bronchiectasis Registry (IRIDE) was conducted. Adults with non-CF bronchiectasis were enrolled across 18 Italian sites between 2015 and 2019. Among the 1,098 patients (mean age: 63.5 years; 67% female) enrolled, the most frequent aetiologies were idiopathic (48%), post-infective (16%), COPD (9.9%) and immunodeficiency (4.9%). Co-existing asthma was present in 21% of the cohort. Using the Bronchiectasis Severity Index, 33% were classified as mild, 37% moderate and 30% severe. The mean exacerbation rate at baseline was 2.2/year. The most frequent pathogens giving chronic infection were P. aeruginosa (19%), H. influenzae (6%) and S. aureus (4%). The mean FEV1%pred was 81%, and 69% of patients were treated with inhaled corticosteroids with and without bronchodilators. Mucoactive drugs and macrolides were used by 7% of patients, while inhaled antibiotics were rarely used (1.5%). Chest physiotherapy was practiced by only 42% of participants at baseline. Using previous published quality standards for bronchiectasis, including testing for immunoglobulins (56%), ABPA (50%), use of chest physiotherapy (42%), P. aeruginosa eradication for new isolates (25%), bronchodilators (62%) and pulmonary rehabilitation (21%) for patients with significant breathlessness, and prophylactic antibiotics for frequent exacerbators (11%), none exceeded the recommended 80% target. Italian patients with bronchiectasis are predominantly idiopathic with a high rate of P. aeruginosa infection. Quality standards for bronchiectasis management are not met across Italy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.